Literature DB >> 11417759

Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.

A M Vandamme1, F Houyez, D Bànhegyi, B Clotet, G De Schrijver, K A De Smet, W W Hall, R Harrigan, N Hellmann, K Hertogs, C Holtzer, B Larder, D Pillay, E Race, J C Schmit, R Schuurman, E Schulse, A Sönnerborg, V Miller.   

Abstract

HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken into consideration in the choice of a specific combination therapy. Guidelines recommending resistance testing in certain circumstances have been issued. Many clinicians have access to resistance testing and will increasingly use these results in their treatment decisions. In this document, we comment on the different methods available, and the relevant issues relating to the clinical application of these tests. Specifically, the following recommendations can be made: (i) genotypic and phenotypic HIV-1 drug resistance analyses can yield complementary information for the clinician. However, insufficient information currently exists as to which approach is preferable in any particular clinical setting; (ii) when HIV-1 drug resistance testing is required, it is recommended that testing be performed on plasma samples obtained before starting, stopping or changing therapy, on samples that have a viral load above the detection limit of the resistance test; (iii) the panel recommends that genotypic and phenotypic HIV-1 drug resistance testing for clinical purposes be performed in a certified laboratory under strict quality control and quality assurance standards; and (iv) the panel recommends that resistance testing laboratories provide clinicians with resistance reports that include a list of drug-related resistance mutations (genotype) and/or a list of drug-related fold resistance values (phenotype), with interpretations of each by an experienced virologist. The interpretation of genotypic and phenotypic analysis is a complex and developing science, and in order to understand HIV-1 drug resistance reports, communication between the requesting clinician and the expert that interpreted the resistance report is recommended.

Entities:  

Mesh:

Year:  2001        PMID: 11417759

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms.

Authors:  Jaideep Ravela; Bradley J Betts; Francoise Brun-Vézinet; Anne-Mieke Vandamme; Diane Descamps; Kristel van Laethem; Kate Smith; Jonathan M Schapiro; Dean L Winslow; Caroline Reid; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

2.  Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs.

Authors:  Tomoko Chiba-Mizutani; Hideka Miura; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Kosuke Miyauchi; Masako Nishizawa; Naoki Yamamoto; Wataru Sugiura
Journal:  J Clin Microbiol       Date:  2006-12-20       Impact factor: 5.948

3.  Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.

Authors:  Shigeru Yoshida; Junko Hattori; Masakazu Matsuda; Kiyomi Okada; Yukumasa Kazuyama; Osamu Hashimoto; Shiro Ibe; Shin-ichi Fujisawa; Hitoshi Chiba; Masashi Tatsumi; Shingo Kato; Wataru Sugiura
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12-03       Impact factor: 2.205

Review 4.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

5.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Authors:  Samir Abdurahman; Akos Végvári; Masoud Youssefi; Michael Levi; Stefan Höglund; Elin Andersson; Peter Horal; Bo Svennerholm; Jan Balzarini; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

7.  Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.

Authors:  Klaus Korn; Heide Reil; Hauke Walter; Barbara Schmidt
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

8.  "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Authors:  Luke C Swenson; Graham Pollock; Brian Wynhoven; Theresa Mo; Winnie Dong; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.